Search results
Results from the WOW.Com Content Network
Romosozumab is used for osteoporosis to decrease the risk of fractures. [10] Two trials found that it reduced the rate of vertebral fracture. In one, there was a 73% lower risk of vertebral fracture after one year, and the benefit was maintained after a second year of taking denosumab.
In those with postmenopausal osteoporosis denosumab decreases the risk of fractures but increases the risk of infection. [19] A 2013 review concluded that it is a reasonable treatment for postmenopausal osteoporosis. [20] A 2017 review did not find benefit in males. [21]
Zoledronic acid is used for the treatment of osteoporosis in men and post-menopausal women at increased risk of fracture. [ 13 ] [ 14 ] In 2007, the US Food and Drug Administration (FDA) approved zoledronic acid for the treatment of postmenopausal osteoporosis .
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium. [medical citation needed]
Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. [4] It is taken by mouth. [4] Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes. [4]
Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa.
Treatment of osteoporosis or non-malignant bone disease with denosumab (not taking systemic glucocorticoids) High: Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years